Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 with GM-CSF with or without low-dose cyclophosphamide in advanced renal cell carcinoma
2006-006370-25Phase 2Completed
- Sponsor
- Immatics
- Start
- Mar 2007
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IMA901 in renal cell carcinoma (RCC) (2 arms), sponsored by Immatics. Primary endpoint: Disease control rate at Visit 14. Started Mar 2007; status: completed.
02
Drugs
IMA901
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-006370-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006370-25.